Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 5/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 7/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30522345 | 1.00 | BTK (0.34) | BTKBDKRB1DRD2HTR1DDRD3 | |
| SCHEMBL20533142 | 0.84 | DRD2 (0.41) | BDKRB1DRD2HTR1DDRD3 | |
| SCHEMBL20533140 | 0.84 | DRD2 (0.41) | BDKRB1DRD2HTR1DDRD3 | |
| SCHEMBL26052179 | 0.82 | EPAS1 (0.34) | BTKBDKRB1DRD2HTR1DDRD3 | |
| SCHEMBL2629484 | 0.81 | TAS1R3 (0.44) | BDKRB1DRD2HTR1DDRD3 | |
| SCHEMBL3532957 | 0.81 | TAS1R3 (0.44) | BDKRB1DRD2HTR1DDRD3 | |
| SCHEMBL29766427 | 0.79 | BTK (0.39) | BTK | |
| SCHEMBL20683066 | 0.79 | BTK (0.39) | BTK | |
| SCHEMBL25489095 | 0.76 | DRD2 (0.33) | DRD2HTR1DDRD3 | |
| SCHEMBL26073296 | 0.75 | BTK (0.35) | BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117567453-A | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 渤健马萨诸塞州股份有限公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3609886-B1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4249071-A2 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-110621670-B | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 比奥根MA公司 | 2023-09-15 | — | — | CN | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2023-05-11 | — | — | US | disclosed |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2022-08-30 | — | — | US | disclosed |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2021-11-04 | — | — | US | disclosed |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2020-07-30 | — | — | US | disclosed |
| EP-3609886-A1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2020-02-19 | — | — | EP | disclosed |
| CN-110621670-A | Benzazepine analogs as inhibitors of bruton's tyrosine kinase | 比奥根MA公司 | 2019-12-27 | — | — | CN | disclosed |
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180362522-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-12-20 | — | — | US | disclosed |
| US-20180297992-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. | 2018-10-18 | — | — | US | disclosed |
| WO-2018191577-A1 | BENZOAZEPINE ANALOGS AS INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | BIOGEN MA INC. (US) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227341-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-10961237-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-20210340135-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-20180362522-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-20200239459-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-11427577-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-20180297992-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-10189829-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-11858926-B2 | Inhibiting agents for bruton's tyrosine kinase | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
| US-20230147490-A1 | INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | BTK 2/4885BDKRB1 966/4885DRD2 4832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.